What is Leerink Partnrs' Estimate for KYMR Q3 Earnings?
Investment analysts at Leerink Partners have issued their Q3 2026 earnings estimates for Kymera Therapeutics, predicting an EPS of ($1.09). The consensus for the full year is ($2.79) per share. Other brokerages have provided varying ratings and price targets, with an average target price of $59.11. Kymera's stock has seen a 5.4% increase, currently priced at $39.71, with a market cap of $2.59 billion. The company reported a loss of ($0.95) EPS for the last quarter, missing estimates, and revenue decreased by 55.1% year-over-year.
- Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2026 earnings estimates for shares of Kymera Therapeutics in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst F. Khurshid expects that the company will post earnings per share of ($1.09) for the quarter. The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q4 2026 earnings at ($1.11) EPS.
A number of other brokerages have also recently commented on KYMR. Oppenheimer reissued an "outperform" rating and issued a $53.00 price objective (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Jefferies Financial Group set a $64.00 price target on shares of Kymera Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, June 25th. The Goldman Sachs Group raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. Morgan Stanley initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price target for the company. Finally, Wells Fargo & Company dropped their price target on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, June 26th. Two investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $59.11.
Get Kymera Therapeutics alerts:
Get Our Latest Stock Analysis on Kymera Therapeutics
Kymera Therapeutics Stock Up 5.4%
Shares of NASDAQ:KYMR opened at $39.71 on Wednesday. Kymera Therapeutics has a 52 week low of $19.44 and a 52 week high of $53.27. The stock has a market capitalization of $2.59 billion, a P/E ratio of -11.54 and a beta of 2.18. The firm has a fifty day simple moving average of $44.93 and a two-hundred day simple moving average of $36.45.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.12). The company had revenue of $11.48 million during the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative net margin of 616.03% and a negative return on equity of 32.86%. The business's revenue was down 55.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.58) earnings per share.
Insider Buying and Selling at Kymera Therapeutics
In other Kymera Therapeutics news, Director Jeffrey W. Albers sold 6,349 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bvf Partners L. P/Il purchased 317,167 shares of the business's stock in a transaction on Monday, June 30th. The shares were bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares in the company, valued at $123,146,980. This represents a 12.78% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 48,349 shares of company stock worth $2,334,301 in the last three months. 16.01% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. increased its stake in shares of Kymera Therapeutics by 30.3% in the fourth quarter. Franklin Resources Inc. now owns 38,367 shares of the company's stock worth $1,544,000 after acquiring an additional 8,927 shares during the period. Geode Capital Management LLC increased its stake in shares of Kymera Therapeutics by 5.0% in the fourth quarter. Geode Capital Management LLC now owns 1,105,487 shares of the company's stock worth $44,484,000 after acquiring an additional 52,263 shares during the period. Wells Fargo & Company MN increased its stake in shares of Kymera Therapeutics by 51.8% in the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after acquiring an additional 7,487 shares during the period. Summit Investment Advisors Inc. increased its stake in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after acquiring an additional 406 shares during the period. Finally, Affinity Asset Advisors LLC acquired a new stake in shares of Kymera Therapeutics in the fourth quarter worth $1,609,000.
Kymera Therapeutics Company Profile
(Get Free Report)Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More
- Five stocks we like better than Kymera Therapeutics
- How to Start Investing in Real Estate
- Data Centers in Demand—This REIT Owns a Whole Portfolio
- Stock Average Calculator
- 3 Battery Stocks to Buy and Hold for the Rest of the Decade
- What is the Nikkei 225 index?
- 3 Stocks to Consider as Tension Builds in Energy Markets
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Kymera Therapeutics Right Now?
Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
